Navigation Links
CSIRO deal to commercialize 'artificial gut'
Date:6/9/2009

CSIRO Food Futures National Research Flagship and Australian company Stadvis Pty Ltd have signed a worldwide license agreement to commercialise an automated instrument that accurately predicts glycemic index (GI) and resistant starch (RS) in food products.

The machine will provide the food industry with an accurate means of testing the functional properties and potential human health benefits of new foods that is much quicker and more cost-effective than the current in vivo (human) method.

The GI and RS Analyser is the first of its kind in the world. The prototype works by mimicking the human digestion process and was originally developed to test the properties of new grains being developed by the Flagship.

Dr Bruce Lee, Director of the Food Futures Flagship, said this commercialisation agreement will help address the growing global demand for foods with defined health benefits through low GI and higher fibre content particularly resistant starch.

"Its principal purpose is to help food manufacturers develop a wider range of healthy food products far more cheaply and quickly than possible previously. It can also be used to screen germplasm for functional grain attributes," Dr Lee said.

"With the growing problem of obesity, diabetes and cardiovascular disease in Australia and around the world, there is increasing demand for low GI and foods high in resistant starch. Consumers need greater access to products with appropriate health benefits, and we believe this new GI and RS predictor will help achieve that goal," he said.

CSIRO awarded the license to commercialise the machine following an open Expression of Interest announcement by the CSIRO. Stadvis Managing Director, Mr Phillip Clancy, said the new instrument will be a valuable addition to his company's portfolio.

"Stadvis is pleased to have won the opportunity to partner with CSIRO to bring this technology to market. The new device will be marketed to food manufacturing companies and laboratories around the world," he said.

Until now predicting GI involved feeding the test food to a number of human volunteers and taking regular blood samples over the following hours to monitor changing blood sugar levels. This new machine can replace this expensive and time consuming process in the development phase of products, leaving the standard in vivo (human) test to the final stage of food development and labelling procedures.

CSIRO initiated the National Research Flagships to provide science-based solutions in response to Australia's major research challenges and opportunities. The nine Flagships form multidisciplinary teams with industry and the research community to deliver impact and benefits for Australia.


'/>"/>

Contact: Owen Craig
Owen.Craig@csiro.au
61-294-908-201
CSIRO Australia
Source:Eurekalert  

Related biology news :

1. CSIRO enlisted to avert global wheat supply crisis
2. MSU technology that converts plant fibers to biofuel commercialized
3. Progress toward artificial tissue?
4. Non-wovens as scaffolds for artificial tissue
5. Development of an artificial simulator of the nervous system to do research into diseases
6. Red pandas reveal an unexpected (artificial) sweet tooth
7. Artificial cells, simple model for complex structure
8. TECNALIA uses artificial vision to improve recycling of electronic scrap metal
9. Biomedical researchers create artificial human bone marrow in a test tube
10. Scientists identify cell changes leading to impaired artificial kidney function
11. Evolved Machines Selected as a Prime Contractor for DARPA Program to Engineer an Artificial Olfaction System
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
CSIRO deal to commercialize 'artificial gut'
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology: